See more : Alujain Corporation (2170.SR) Income Statement Analysis – Financial Results
Complete financial analysis of FibroBiologics, Inc. Common Stock (FBLG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of FibroBiologics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MARBLE CITY INDIA LIMITED (MARBLE.BO) Income Statement Analysis – Financial Results
- Rodium Realty Limited (RODIUM.BO) Income Statement Analysis – Financial Results
- Rocky Mountain Chocolate Factory, Inc. (RMCF) Income Statement Analysis – Financial Results
- MICT, Inc. (MICT) Income Statement Analysis – Financial Results
- Banco Espírito Santo, S.A. (BKESF) Income Statement Analysis – Financial Results
FibroBiologics, Inc. Common Stock (FBLG)
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 94.00K | 0.00 | 0.00 |
| Gross Profit | -437.00K | -94.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.37M | 1.15M | 521.00K | 669.00K |
| General & Administrative | 5.84M | 3.32M | 1.06M | 500.00K |
| Selling & Marketing | 685.00K | -94.00K | 0.00 | 0.00 |
| SG&A | 6.52M | 3.23M | 1.06M | 500.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.89M | 4.37M | 1.58M | 1.17M |
| Cost & Expenses | 8.89M | 4.47M | 1.58M | 1.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 147.00K | 654.00K | 4.00K | 0.00 |
| Depreciation & Amortization | 437.00K | 94.00K | 0.00 | 1.17M |
| EBITDA | -15.90M | -4.37M | -1.58M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -4.47M | -1.58M | -1.17M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.60M | -654.00K | -4.00K | 0.00 |
| Income Before Tax | -16.49M | -5.12M | -1.58M | -1.17M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -16.49M | -5.12M | -1.58M | -1.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.59 | -0.16 | -0.05 | -0.13 |
| EPS Diluted | -0.68 | -0.16 | -0.05 | -0.13 |
| Weighted Avg Shares Out | 32.49M | 32.49M | 32.49M | 8.75M |
| Weighted Avg Shares Out (Dil) | 28.23M | 32.49M | 32.49M | 8.75M |
FibroBiologics to Present at the BIO International Convention 2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today data...
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,...
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
HOUSTON , March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced...
FibroBiologics to Present at Advanced Wound Care Summit USA
HOUSTON , March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,...
FibroBiologics Appoints Ruben A. Garcia as General Counsel
HOUSTON , March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced...
FibroBiologics Files 2023 Form 10-K Annual Report
HOUSTON , Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials...
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
HOUSTON , Feb. 13, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials encompassing 150+ patents issued and pending, presented preclinical data that...
Source: https://incomestatements.info
Category: Stock Reports